Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
Ernexa Therapeutics was selected for the Emerging Track at the 2026 Cell & Gene Meeting on the Mesa, with CEO Sanjeev Luther delivering an Innovation Spotlight presentation on October 6, 2026. The presentation will focus on ERNA-101, the company's lead cell therapy candidate, initially targeting platinum-resistant ovarian cancer, supported by preclinical data showing complete tumor clearance in combination with anti-PD-1 therapy.
Key figures
- Preclinical result
- ERNA-101 + anti-PD-1 achieved complete tumor clearance and long-term survival in two-thirds of treated animals in independent CRO study; earlier ovarian cancer study showed complete tumor clearance and 100% survival
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.